A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation

NCT05745740 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: RC48-ADC
DRUG: Pyrotinib

Sponsor

RemeGen Co., Ltd.